| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on June 14, 2007
Accepted on November 17, 2007
in Human Vascular Endothelial Cells
From the Institute of Cardiovascular Science and Key Laboratory of Molecular Cardiovascular Science (Y.F., Y.W., Z.T., H.Z., X.Q., Y.Z., Y.G., X.W., N.W.), Peking University, Beijing, China; the Diabetes Center (Y.F., Y.W., Z.T., H.Z., X.Q., Y.Z. Y.G., X.W., N.W.), Peking University, Beijing, China; the Institut Pasteur de Lille (B.S.) INSERM U545, Université de Lille 2, Faculté de Pharmacie et Faculté de Médecine, Lille, France; and the Departments of Bioengineering and Medicine (S.C., N.W.), University of California San Diego, La Jolla, Calif.
* To whom correspondence should be addressed. E-mail: npwang{at}bjmu.edu.cn.
Objective—Endothelial activation is implicated in atherogenesis and diabetes. The role of peroxisome proliferator-activated receptor-
(PPAR-
) in endothelial activation remains poorly understood. In this study, we investigated the antiinflammatory effect of PPAR-
and the mechanism involved.
Methods and Results—In human umbilical vein endothelial cells (HUVECs), the synthetic PPAR-
ligands GW0742 and GW501516 significantly inhibited tumor necrosis factor (TNF)-
–induced expression of vascular cell adhesion molecule-1 and E-selectin (assayed by real-time RT-PCR and Northern blotting), as well as the ensuing endothelial-leukocyte adhesion. Activation of PPAR-
upregulated the expression of antioxidant genes superoxide dismutase 1, catalase, and thioredoxin and decreased reactive oxygen species production in ECs. Chromatin immunoprecipitation assays showed that GW0742 switched the association of BCL-6, a transcription repressor, from PPAR-
to the vascular cell adhesion molecule (VCAM)-1 promoter. Small interfering RNA reduced endogenous PPAR-
expression but potentiated the suppressive effect of GW0742 on EC activation, which suggests that the nonliganded PPAR-
may have an opposite effect.
Conclusions—We have demonstrated that ligand activation of PPAR-
in ECs has a potent antiinflammatory effect, probably via a binary mechanism involving the induction of antioxidative genes and the release of nuclear corepressors. PPAR-
agonists may have a potential for treating inflammatory diseases such as atherosclerosis and diabetes.
This article has been cited by other articles:
![]() |
W. Shan, P. S. Palkar, I. A. Murray, E. I. McDevitt, M. J. Kennett, B. H. Kang, H. C. Isom, G. H. Perdew, F. J. Gonzalez, and J. M. Peters Ligand Activation of Peroxisome Proliferator-Activated Receptor {beta}/{delta} (PPAR{beta}/{delta}) Attenuates Carbon Tetrachloride Hepatotoxicity by Downregulating Proinflammatory Gene Expression Toxicol. Sci., October 1, 2008; 105(2): 418 - 428. [Abstract] [Full Text] [PDF] |
||||
|
ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2007 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |